Pharsight

Drug Patents Expiring in 2030

1. List of Abilify Mycite Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8847766 OTSUKA Pharma-informatics system
Mar, 2030

(6 years from now)

US8545402 OTSUKA Highly reliable ingestible event markers and methods for using the same
Apr, 2030

(6 years from now)

US8114021 OTSUKA Body-associated receiver and method
Jun, 2030

(7 years from now)

US11464423 OTSUKA In-body power source having high surface area electrode
Sep, 2030

(7 years from now)

US9941931 OTSUKA System for supply chain management
Nov, 2030

(7 years from now)

US8961412 OTSUKA In-body device with virtual dipole signal amplification
Nov, 2030

(7 years from now)

US8258962 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Nov, 2030

(7 years from now)

US8547248 OTSUKA Implantable zero-wire communications system
Dec, 2030

(7 years from now)

Do you want to check out ABILIFY MYCITE KIT patents from before 2022?

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

117

United States

36

Japan

26

European Union

23

Israel

19

Canada

16

China

16

Taiwan

15

Korea, Republic of

11

Australia

9

Hong Kong

8

Brazil

7

Singapore

6

Malaysia

6

Denmark

6

Mexico

5

Spain

5

Russia

5

South Africa

4

India

3

Ukraine

3

Portugal

2

New Zealand

2

Chile

1

Poland

1

Morocco

EA

1

EA

1

Cyprus

1

Peru

1

Costa Rica

1

Ecuador

1

Finland

1

Tunisia

1

Slovenia

2. List of Acetaminophen drug patents

ACETAMINOPHEN's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741959 FRESENIUS KABI USA Paracetamol for parenteral administration
Apr, 2030

(6 years from now)

Do you want to check out ACETAMINOPHEN patents from before 2022?

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 28 October, 2015

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ACETAMINOPHEN family patents

4

European Union

3

United States

2

Poland

2

Spain

2

Denmark

1

China

1

Hong Kong

1

Brazil

1

Portugal

1

Japan

1

Australia

1

Hungary

3. List of Acuvue Theravision With Ketotifen drug patents

ACUVUE THERAVISION WITH KETOTIFEN Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9962376 JOHNSON JOHNSON VISN Methods and ophthalmic devices used in the treatment of ocular allergies
Jun, 2030

(7 years from now)

Do you want to check out ACUVUE THERAVISION WITH KETOTIFEN patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Feb 25, 2025

Drugs and Companies using KETOTIFEN FUMARATE ingredient

Market Authorisation Date: 25 February, 2022

Treatment: NA

Dosage: DRUG-ELUTING CONTACT LENS ;OPHTHALMIC

More Information on Dosage

ACUVUE THERAVISION WITH KETOTIFEN family patents

5

United States

5

European Union

2

Spain

2

China

1

Korea, Republic of

1

Russia

1

Hong Kong

1

Brazil

1

Canada

1

Taiwan

1

Singapore

1

Argentina

1

Japan

1

Australia

1

Hungary

4. List of Airsupra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415009 BOND Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(6 years from now)

Do you want to check out AIRSUPRA patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Jan 10, 2026

Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient

Market Authorisation Date: 10 January, 2023

Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

AIRSUPRA family patents

26

United States

10

Japan

9

Taiwan

8

Lithuania

8

Hungary

7

Russia

7

Korea, Republic of

7

Australia

6

Spain

6

Hong Kong

6

Denmark

6

Poland

6

China

6

Argentina

6

Croatia

6

Portugal

6

Slovenia

6

European Union

5

Cyprus

4

Mexico

3

Brazil

3

Canada

3

Ukraine

3

San Marino

3

Israel

3

South Africa

2

Norway

2

Luxembourg

1

Philippines

1

ME

1

Netherlands

5. List of Akynzeo drug patents

AKYNZEO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943515 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US11559523 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US8623826 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US8951969 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(7 years from now)

Do you want to check out AKYNZEO patents from before 2022?

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limite...

Dosage: CAPSULE;ORAL

More Information on Dosage

AKYNZEO family patents

11

United States

6

China

4

Spain

4

European Union

3

Poland

3

Croatia

2

Hong Kong

2

Denmark

2

RS

2

San Marino

2

Cyprus

2

Portugal

2

Slovenia

IB

1

IB

1

Dominican Republic

1

Malaysia

AP

1

AP

1

Brazil

1

Canada

1

Ukraine

1

Morocco

EA

1

EA

1

Japan

1

Nicaragua

1

New Zealand

1

Korea, Republic of

1

Guatemala

1

Peru

1

Israel

1

Chile

1

Taiwan

1

Georgia

1

Mexico

1

Australia

1

Cuba

1

Costa Rica

1

Ecuador

1

South Africa

1

Colombia

1

Lithuania

1

Tunisia

1

Hungary

6. List of Akynzeo drug patents

AKYNZEO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(7 years from now)

Do you want to check out AKYNZEO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 2022-04-19

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of AKYNZEO before it's patent expiration?
More Information on Dosage

AKYNZEO family patents

11

United States

6

China

4

Spain

4

European Union

3

Poland

3

Croatia

2

Hong Kong

2

Denmark

2

RS

2

San Marino

2

Cyprus

2

Portugal

2

Slovenia

IB

1

IB

1

Dominican Republic

1

Malaysia

AP

1

AP

1

Brazil

1

Canada

1

Ukraine

1

Morocco

EA

1

EA

1

Japan

1

Nicaragua

1

New Zealand

1

Korea, Republic of

1

Guatemala

1

Peru

1

Israel

1

Chile

1

Taiwan

1

Georgia

1

Mexico

1

Australia

1

Cuba

1

Costa Rica

1

Ecuador

1

South Africa

1

Colombia

1

Lithuania

1

Tunisia

1

Hungary

7. List of Alecensa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9440922 HOFFMANN-LA ROCHE Tetracyclic compound
Jun, 2030

(7 years from now)

Do you want to check out ALECENSA patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's patent expiration?
More Information on Dosage

ALECENSA family patents

6

United States

4

Japan

4

Hungary

4

European Union

3

Spain

3

Denmark

3

Poland

3

Croatia

3

Portugal

3

Lithuania

3

Slovenia

2

Russia

2

Norway

2

Taiwan

1

Hong Kong

1

Malaysia

1

RS

1

China

1

Brazil

1

Canada

1

Ukraine

1

Singapore

1

Morocco

1

Argentina

1

New Zealand

1

Korea, Republic of

1

Cyprus

1

Peru

1

Israel

1

Chile

1

Mexico

1

Australia

1

Costa Rica

1

Ecuador

1

Netherlands

1

South Africa

1

Colombia

1

Luxembourg

8. List of Amondys 45 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10287586 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

US9228187 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758783 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

US10781450 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

Do you want to check out AMONDYS 45 patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 25, 2028
New Chemical Entity Exclusivity (NCE) Feb 25, 2026

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: 2025-02-25

Market Authorisation Date: 25 February, 2021

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; Treatment of duchenne muscular dystrophy (dmd) in patients who have...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AMONDYS 45 family patents

7

United States

6

Korea, Republic of

6

Australia

5

Japan

5

Israel

4

New Zealand

2

China

2

European Union

1

Spain

1

Turkey

1

Denmark

1

RS

1

Poland

1

Brazil

1

Canada

1

Croatia

1

Cyprus

1

Portugal

1

Lithuania

1

Slovenia

1

Hungary

9. List of Amzeeq drug patents

Can you believe AMZEEQ received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086080 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US10265404 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(7 years from now)

US10821187 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(7 years from now)

US10213512 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US8992896 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US9675700 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US8865139 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US10137200 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(7 years from now)

US10517882 JOURNEY Method for healing of an infected acne lesion without scarring
Oct, 2030

(7 years from now)

US8945516 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(7 years from now)

Do you want to check out AMZEEQ patents from before 2022?

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 October, 2019

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of AMZEEQ before it's patent expiration?
More Information on Dosage

AMZEEQ family patents

52

United States

IB

5

IB

5

Canada

2

Israel

2

Australia

1

China

1

Brazil

1

South Africa

1

Mexico

1

United Kingdom

1

European Union

10. List of Anjeso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253478 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(6 years from now)

US9974746 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(6 years from now)

US10709713 BAUDAX Nanoparticulate meloxicam formulations
May, 2030

(6 years from now)

Do you want to check out ANJESO patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ANJESO family patents

20

United States

8

Japan

6

European Union

3

Spain

2

Canada

2

Denmark

2

Hungary

1

Germany

1

Austria

1

Taiwan

1

Australia

11. List of Anoro Ellipta drug patents

ANORO ELLIPTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(6 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

Do you want to check out ANORO ELLIPTA patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

17

United States

8

Australia

7

European Union

6

Korea, Republic of

6

United Kingdom

5

China

5

Japan

4

Brazil

4

Canada

4

Hungary

3

Spain

3

Denmark

3

Poland

3

Norway

3

New Zealand

3

Israel

3

Portugal

3

South Africa

2

Malaysia

2

Singapore

2

Cyprus

2

Peru

2

Mexico

2

Lithuania

1

Hong Kong

1

Dominican Republic

1

Turkey

1

RS

1

Russia

1

Ukraine

1

Morocco

1

Argentina

EA

1

EA

1

ME

1

Croatia

1

Chile

1

Taiwan

1

Slovenia

1

Costa Rica

1

Colombia

1

Luxembourg

12. List of Apadaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9132125 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(7 years from now)

US9549923 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
Jul, 2030

(7 years from now)

US8748413 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828978 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(7 years from now)

Do you want to check out APADAZ patents from before 2022?

Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 February, 2018

Treatment: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Dosage: TABLET;ORAL

More Information on Dosage

APADAZ family patents

17

United States

5

Korea, Republic of

2

Israel

2

South Africa

2

European Union

1

Malaysia

1

China

1

Russia

1

Brazil

1

Canada

1

Ukraine

1

Singapore

1

Japan

1

New Zealand

1

Chile

1

Mexico

1

Australia

1

Cuba

1

Costa Rica

1

Colombia

13. List of Apriso drug patents

APRISO Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865688 VALEANT PHARMS INTL Compositions and methods for treatment of bowel diseases with granulated mesalamine
May, 2030

(6 years from now)

Do you want to check out APRISO patents from before 2022?

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 31 October, 2008

Treatment: For the maintenance of remission of ulcerative colitis

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of APRISO before it's patent expiration?
More Information on Dosage

APRISO family patents

5

United States

1

New Zealand

1

China

1

Israel

1

Canada

1

South Africa

1

Ukraine

1

Chile

EA

1

EA

1

Mexico

1

Japan

1

Australia

1

European Union

14. List of Aptiom drug patents

APTIOM's oppositions filed in EPO
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8372431 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Apr, 2030

(6 years from now)

Do you want to check out APTIOM patents from before 2022?

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Market Authorisation Date: 08 November, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's patent expiration?
More Information on Dosage

APTIOM family patents

6

United States

4

Japan

3

Korea, Republic of

3

Portugal

2

Spain

2

European Union

1

Denmark

1

RS

1

Poland

1

Russia

1

China

1

Brazil

1

Canada

1

Ukraine

1

Argentina

1

Croatia

1

Cyprus

1

Mexico

1

Australia

1

Lithuania

1

Slovenia

1

Hungary

15. List of Aristada drug patents

ARISTADA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

Do you want to check out ARISTADA patents from before 2022?

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA family patents

21

United States

7

Japan

4

Canada

3

European Union

2

Spain

2

Argentina

2

New Zealand

2

Australia

1

Hong Kong

1

Denmark

1

RS

1

Poland

1

Croatia

1

Cyprus

1

Portugal

1

Taiwan

1

Lithuania

1

Saudi Arabia

1

Slovenia

1

Hungary

16. List of Aristada Initio Kit drug patents

ARISTADA INITIO KIT's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

Do you want to check out ARISTADA INITIO KIT patents from before 2022?

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA INITIO KIT family patents

21

United States

7

Japan

4

Canada

3

European Union

2

Spain

2

Argentina

2

New Zealand

2

Australia

1

Hong Kong

1

Denmark

1

RS

1

Poland

1

Croatia

1

Cyprus

1

Portugal

1

Taiwan

1

Lithuania

1

Saudi Arabia

1

Slovenia

1

Hungary

17. List of Arnuity Ellipta drug patents

ARNUITY ELLIPTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(6 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

Do you want to check out ARNUITY ELLIPTA patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Mar 1, 2026

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 20 August, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARNUITY ELLIPTA family patents

5

United States

5

United Kingdom

3

Japan

3

Korea, Republic of

2

Spain

2

Denmark

2

Poland

2

China

2

Brazil

2

Canada

2

Norway

2

New Zealand

2

Israel

2

Portugal

2

Australia

2

South Africa

2

Hungary

2

European Union

1

Malaysia

1

Argentina

1

Cyprus

1

Taiwan

1

Mexico

18. List of Atrovent Hfa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447 BOEHRINGER INGELHEIM Inhaler device
Jan, 2030

(6 years from now)

Do you want to check out ATROVENT HFA patents from before 2022?

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 27 November, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

ATROVENT HFA family patents

2

European Union

1

United States

1

Poland

1

Germany

1

Spain

1

Canada

1

Japan

1

Denmark

1

Hungary

19. List of Aubagio drug patents

AUBAGIO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735 SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Sep, 2030

(7 years from now)

Do you want to check out AUBAGIO patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Apr 30, 2024
Pediatric Exclusivity (PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's patent expiration?
More Information on Dosage

AUBAGIO family patents

8

United States

4

China

3

Israel

3

European Union

2

Hong Kong

2

Russia

2

Ukraine

2

New Zealand

2

Peru

2

Chile

2

Taiwan

2

Australia

2

Costa Rica

1

Uruguay

1

Spain

1

Dominican Republic

1

Malaysia

1

Denmark

1

RS

1

Poland

1

Brazil

1

Canada

1

Morocco

1

Argentina

1

Japan

1

ME

1

Nicaragua

1

Croatia

1

Honduras

1

Korea, Republic of

1

Guatemala

1

Cyprus

1

Portugal

1

Jordan

1

Mexico

1

Colombia

1

Lithuania

1

Tunisia

1

Slovenia

1

Hungary

20. List of Auryxia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387191 KERYX BIOPHARMS Ferric citrate dosage forms
Jul, 2030

(7 years from now)

US10300039 KERYX BIOPHARMS Ferric citrate dosage forms
Jul, 2030

(7 years from now)

Do you want to check out AURYXIA patents from before 2022?

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorus levels

Dosage: TABLET;ORAL

More Information on Dosage

AURYXIA family patents

9

United States

9

Taiwan

3

Korea, Republic of

3

China

2

Russia

1

Israel

1

Canada

1

Brazil

1

Ukraine

1

Mexico

1

Australia

1

European Union

21. List of Avycaz drug patents

AVYCAZ's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835455 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Oct, 2030

(7 years from now)

Do you want to check out AVYCAZ patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
New Patient Population (NPP) Dec 20, 2025
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 2024-02-26

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

AVYCAZ family patents

7

United States

4

Japan

4

Korea, Republic of

4

European Union

3

China

2

Spain

2

Russia

2

Brazil

2

Israel

1

Hong Kong

1

Malaysia

1

Turkey

1

Denmark

1

Poland

1

Canada

1

France

1

Cyprus

1

Portugal

1

Mexico

1

Australia

1

Slovenia

1

Hungary

22. List of Besivance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8604020 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Mar, 2030

(6 years from now)

US8415342 BAUSCH AND LOMB Besifloxacin ophthalmic composition for the treatment or control of infection
Nov, 2030

(7 years from now)

Do you want to check out BESIVANCE patents from before 2022?

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2009

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

BESIVANCE family patents

7

United States

1

Korea, Republic of

1

China

1

Brazil

1

Canada

1

Taiwan

1

Argentina

1

Mexico

1

Japan

1

European Union

23. List of Bevespi Aerosphere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9463161 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(6 years from now)

US8808713 ASTRAZENECA Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(6 years from now)

US8703806 ASTRAZENECA Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(6 years from now)

US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(6 years from now)

US10716753 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(6 years from now)

US8324266 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(6 years from now)

Do you want to check out BEVESPI AEROSPHERE patents from before 2022?

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

BEVESPI AEROSPHERE family patents

26

United States

10

Japan

9

Taiwan

8

Lithuania

8

Hungary

7

Russia

7

Korea, Republic of

7

Australia

6

Spain

6

Hong Kong

6

Denmark

6

Poland

6

China

6

Argentina

6

Croatia

6

Portugal

6

Slovenia

6

European Union

5

Cyprus

4

Mexico

3

Brazil

3

Canada

3

Ukraine

3

San Marino

3

Israel

3

South Africa

2

Norway

2

Luxembourg

1

Philippines

1

ME

1

Netherlands

24. List of Bevyxxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8987463 PORTOLA PHARMS INC Methods of synthesizing factor Xa inhibitors
Dec, 2030

(7 years from now)

Do you want to check out BEVYXXA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: 2021-06-23

Market Authorisation Date: 23 June, 2017

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

BEVYXXA family patents

4

United States

2

China

2

Japan

1

Spain

1

Canada

1

Portugal

1

Taiwan

1

Argentina

1

European Union

25. List of Beyaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(6 years from now)

Do you want to check out BEYAZ patents from before 2022?

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 24 September, 2010

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BEYAZ before it's patent expiration?
More Information on Dosage

BEYAZ family patents

3

United States

26. List of Braftovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8541575 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Feb, 2030

(6 years from now)

US9593099 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9850230 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

Do you want to check out BRAFTOVI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 2022-06-27

Market Authorisation Date: 27 June, 2018

Treatment: Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the tre...

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's patent expiration?
More Information on Dosage

BRAFTOVI family patents

18

United States

5

European Union

3

Spain

3

Denmark

3

Poland

3

China

EA

3

EA

3

Japan

3

Croatia

3

Cyprus

3

Portugal

3

Lithuania

3

Slovenia

3

Hungary

2

Hong Kong

2

RS

2

Brazil

2

Canada

2

Singapore

2

ME

2

San Marino

2

Chile

2

Mexico

2

Australia

1

Uruguay

1

Austria

1

Dominican Republic

1

Malaysia

1

India

1

Ukraine

1

Morocco

1

Argentina

1

Norway

1

Nicaragua

1

Honduras

1

Korea, Republic of

1

New Zealand

1

Guatemala

1

Peru

1

Israel

1

Georgia

1

Jordan

1

Cuba

1

Costa Rica

1

Ecuador

1

Netherlands

1

South Africa

1

Colombia

1

Luxembourg

1

Tunisia

27. List of Breo Ellipta drug patents

BREO ELLIPTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXO GRP LTD Manifold for use in medicament dispenser
Mar, 2030

(6 years from now)

US8746242 GLAXO GRP LTD Medicament dispenser
Oct, 2030

(7 years from now)

Do you want to check out BREO ELLIPTA patents from before 2022?

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

BREO ELLIPTA family patents

5

United States

5

United Kingdom

3

Japan

3

Korea, Republic of

2

Spain

2

Denmark

2

Poland

2

China

2

Brazil

2

Canada

2

Norway

2

New Zealand

2

Israel

2

Portugal

2

Australia

2

South Africa

2

Hungary

2

European Union

1

Malaysia

1

Argentina

1

Cyprus

1

Taiwan

1

Mexico

28. List of Brexafemme drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188085 SCYNEXIS Antifungal agents
Aug, 2030

(7 years from now)

Do you want to check out BREXAFEMME patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2026
New Indication (I) Nov 30, 2025
Generating Antibiotic Incentives Now (GAIN) Jun 1, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: 2030-06-01

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

More Information on Dosage

BREXAFEMME family patents

3

United States

2

China

1

Hong Kong

1

Canada

1

Japan

1

Australia

1

European Union

29. List of Breztri Aerosphere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9463161 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(6 years from now)

US10716753 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(6 years from now)

US9415009 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(6 years from now)

US8324266 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(6 years from now)

US8808713 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(6 years from now)

US8703806 ASTRAZENECA AB Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(6 years from now)

Do you want to check out BREZTRI AEROSPHERE patents from before 2022?
Exclusivity Exclusivity Expiration
New Combination (NC) Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

BREZTRI AEROSPHERE family patents

26

United States

10

Japan

9

Taiwan

8

Lithuania

8

Hungary

7

Russia

7

Korea, Republic of

7

Australia

6

Spain

6

Hong Kong

6

Denmark

6

Poland

6

China

6

Argentina

6

Croatia

6

Portugal

6

Slovenia

6

European Union

5

Cyprus

4

Mexico

3

Brazil

3

Canada

3

Ukraine

3

San Marino

3

Israel

3

South Africa

2

Norway

2

Luxembourg

1

Philippines

1

ME

1

Netherlands

30. List of Brilinta drug patents

BRILINTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425934 ASTRAZENECA Pharmaceutical compositions
Apr, 2030

(6 years from now)

US8425934

(Pediatric)

 ASTRAZENECA Pharmaceutical compositions
Oct, 2030

(7 years from now)

Do you want to check out BRILINTA patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Nov 5, 2023
M (M) May 9, 2025
Pediatric Exclusivity (PED) Nov 28, 2023

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's patent expiration?
More Information on Dosage

BRILINTA family patents

3

United States

2

Malaysia

2

Russia

2

Japan

2

New Zealand

2

Australia

1

Uruguay

1

Spain

1

Philippines

1

Denmark

1

RS

1

Poland

1

China

1

Brazil

1

Canada

1

Ukraine

1

Singapore

1

Argentina

1

Norway

1

Croatia

1

Korea, Republic of

1

Cyprus

1

Chile

1

Israel

1

Portugal

1

Taiwan

1

Slovenia

1

Mexico

1

South Africa

1

Colombia

1

Lithuania

1

Saudi Arabia

1

Sweden

1

Hungary

1

European Union

31. List of Briviact drug patents

BRIVIACT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653 UCB INC Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
Apr, 2030

(6 years from now)

Do you want to check out BRIVIACT patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Aug 27, 2024

Drugs and Companies using BRIVARACETAM ingredient

Market Authorisation Date: 12 May, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BRIVIACT before it's patent expiration?
More Information on Dosage

BRIVIACT family patents

3

European Union

2

Hong Kong

2

United States

2

China

1

Spain

1

Denmark

1

RS

1

Poland

1

Brazil

1

Canada

EA

1

EA

1

Japan

1

ME

1

Croatia

1

Korea, Republic of

1

San Marino

1

Cyprus

1

Israel

1

Portugal

1

Mexico

1

Australia

1

Slovenia

32. List of Bydureon drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8998876 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(6 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(6 years from now)

US8998876

(Pediatric)

 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(7 years from now)

US8721615

(Pediatric)

 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(7 years from now)

Do you want to check out BYDUREON patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

3

European Union

2

United States

1

Germany

1

Taiwan

1

Switzerland

33. List of Bydureon Bcise drug patents

BYDUREON BCISE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033 ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Oct, 2030

(7 years from now)

Do you want to check out BYDUREON BCISE patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; As an adjunct to diet and exercise to i...

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

8

United States

2

China

2

Japan

2

European Union

1

Spain

1

Denmark

1

Poland

1

Brazil

1

Canada

1

Singapore

EA

1

EA

1

New Zealand

1

Croatia

1

Korea, Republic of

1

Israel

1

Portugal

1

Mexico

1

Australia

1

Lithuania

1

Slovenia

1

Hungary

34. List of Cabometyx drug patents

CABOMETYX's oppositions filed in EPO